<DOC>
	<DOCNO>NCT01632891</DOCNO>
	<brief_summary>The purpose study see antiretroviral therapy ( ART ) safe work get rid malaria blood see whether one type ART good another . This study may offer information research look whether ART play role prevention treatment malaria .</brief_summary>
	<brief_title>Comparing PI-Based nNRTI-based ART Clearance Plasmodium Falciparum Parasitemia HIV-Infected</brief_title>
	<detailed_description />
	<mesh_term>Parasitemia</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<criteria>HIV1 infection CD4+ count &gt; 200 &lt; 350 cells/mm3 obtain within 30 day prior study entry DAIDSapproved laboratory . Pf SCP confirm laboratory approve conduct parasitemia microscopy . Note : Pf SCP define meet three follow criterion within 72 hour prior study entry : Microscopy confirm parasitemia ( see section 6.3.6 A5297 Manual Procedures [ MOPS ] ) An oral temperature &lt; 37.5Â°C temperature The absence Grade 2 great sign symptom thought related clinical malaria include : 1. headache 2. malaise fatigue 3. abdominal discomfort 4. muscle joint pain 5. fever 6. chill 7. perspiration 8. anorexia 9. vomit 10. sign symptom thought related clinical malaria Certain laboratory value obtain within 14 day prior study entry , detailed section 4.1.4 protocol . Hepatitis B surface antigen ( HBsAg ) negative within 30 day prior entry . Female study volunteer reproductive potential must negative serum urine pregnancy test perform within 72 hour prior entry . NOTE : Female study volunteer reproductive potential defined woman reach menarche postmenopausal least 24 consecutive month { i.e. , menses within precede 24 month undergone sterilization procedure ( eg , hysterectomy , bilateral oophorectomy , salpingectomy ) } . Female study volunteer reproductive potential must negative serum urine pregnancy test perform within 72 hour prior entry . NOTE : Female study volunteer reproductive potential defined woman reach menarche postmenopausal least 24 consecutive month { i.e. , menses within precede 24 month undergone sterilization procedure ( eg , hysterectomy , bilateral oophorectomy , salpingectomy ) } . All study volunteer must agree participate conception process ( eg , active attempt become pregnant impregnate , sperm donation , vitro fertilization ) study duration . If participate sexual activity could lead pregnancy , study volunteer must agree use two reliable form contraceptive simultaneously receive protocolspecified medication . One form contraceptive must barrier method participant receive EFV . Participants must agree continue use two contraceptive 6 month stop EFV 6 week stop protocolspecified medication . Note : Female participant unable meet contraception requirement EFV encourage consider NVP . Study volunteer reproductive potential ( girl reach menarche , woman postmenopausal least 24 consecutive month , woman undergo hysterectomy , bilateral oophorectomy salpingectomy , men document azoospermia ) eligible without require use contraceptive . Acceptable documentation sterilization , contraceptive method , menopause write documentation oral communication clinician clinician 's staff document source document one following : Physician report/letter Operative report source documentation patient record Discharge summary Laboratory report azoospermia ( require document successful vasectomy ) FSH measurement elevate menopausal range establish report laboratory EFV per participant 's history drug . Ability willingness participant legal guardian/representative provide inform consent . Willing able return clinic twice three time day study visit . Step 1 : Exclusion Criteria Previous history current use ART . Single dose NVP dual therapy use PMTCT within 2 year prior entry . Use medication antimalarial activity , include TMP/SMX ( see list prohibit medication A5297 MOPS ) , within 14 day prior study entry . Confirmed clinically suspect OIs ( include limit tuberculosis , clinical malaria , PCP ) , pulmonary gastrointestinal infection potential participant complete treatment 30 day prior enrollment sign symptom screen . Breastfeeding . Known allergy/sensitivity hypersensitivity component study drug formulation . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . Serious illness require systemic treatment and/or hospitalization within 30 day prior entry . Results suggestive active pulmonary disease chest xray perform within 30 day prior study entry . Step 2 : Exclusion Criteria There exclusion criterion Step 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>